Jim Cramer recently discussed Amgen Inc. (NASDAQ:AMGN), one of the largest pharmaceutical companies globally, specializing in treatments for various ailments. The stock has gained 10.8% year-to-date due to positive data on its cancer drug. Cramer previously called it a bargain but now suggests a pill form for its cholesterol-lowering drug, Repatha, which currently causes severe pain.

Cramer also commented on Amgen Inc. (NASDAQ:AMGN)’s weight loss drug, MariTide, which is administered once a month, unlike others that are weekly. The market’s negative response caused a stock sell-off despite new data showing less vomiting with lower doses. This reflects the ongoing challenges faced by the company in drug development and market reception.

Read more at Yahoo Finance: Here’s What Jim Cramer Wishes Amgen Inc. (AMGN) Should Do To Its Drug That Hurts Like A “Banshee”